Alcon Stock Rises Following the FDA Approval of TRYPTYR

Stock Information for AngioDynamics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AngioDynamics Inc.

AngioDynamics to Participate in the UBS Global Healthcare Conference
AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.